| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/2 topline data readout example | Phase 1/2 | — | Subscribe to access the data. | Gene Therapies | Ophthalmologic System | ||
Phase 1/2 topline data readout example | Phase 1/2 | — | Subscribe to access the data. | Gene Therapies | Ophthalmologic System | ||
Phase 1/2 topline data readout example | Phase 1/2 | — | Subscribe to access the data. | Gene Therapies | Ophthalmologic System |
Recent Updates
Recently added Catalysts
Opus Genetics, Inc.$3.35
+0.27 (+8.77%)
C 44Pipeline Score Overvalued Pharma · Commercial
Market Cap
346.75 M
EPS
-1.35
P/E Ratio
-
Value Trade
3.75 M
SEC Financials
Q1 2026Dilution Risk
40%Revenue
2.16 M
R&D Expenses
10.58 M
Operating CF
-12.73 M
Total Assets
66.79 M
Total Liabilities
87.89 M
Equity
-45.84 M
D/E Ratio
12,345
-12.88 %
Week
-19.32 %
1 Month
18.01 %
3 Month
120.73 %
6 Month
-7.19 %
5 Year
-100 %
All Time
Cash Data
Cash Position
59.96 M
Monthly Burn
4.24 M
Runway
11.6 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
538.75 K
52 Week Range
0.90 - 5.81
% held by Insiders
18.67 %
% held by Institutions
50.53 %
Enterprise Value
312.72 M
Total Shares
71.10 M
Short %
18.3 %
Float Shares
56.10 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Opus Genetics, Inc.
396Total events
17Upcoming
108Tier-1 (high impact)
2008 – 2029Coverage
Upcoming catalysts 2
TBD
T1Topline Readout
Subscribe to view catalyst details
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 2
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
▲Type B MeetingOPGx-LCA5FiledFDA Meeting
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-30 | Phentolamine Ophthalmic Solution 0.75% | Phase 3 topline data readout | Phase 3 | — | – | – | – |
2026-06-30 | Phentolamine Ophthalmic Solution 0.75% | Phase 3 topline data readout | Phase 3 | — | – | – | – |
2026-06-30 | Phentolamine Ophthalmic Solution 0.75% | Phase 3 topline data readout | Phase 3 | — | – | – | – |
Drug Pipeline Intelligence
C44
Pipeline Score $71M
Pipeline ValueOvervalued
Valuation Signal7
Drugs Scored0.2x
rNPV / MCap Top 68%
Micro Cap (rank 293 of 913)
Percentile RankOpus Genetics, Inc. carries a moderate pipeline score (44/100), with $403M risk-adjusted pipeline value, led by APX3330 in Diabetic Retinopathy (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APX3330 Small molecule | Diabetic Retinopathy | Phase 2 | NCT04692688 | 29% | $164M | COMPLETED | 103 | - | - | Jan 25, 2023 | - | Feb 27, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
OPGx-LCA5 RMATOrphanRare Pediatric | Leber congenital amaurosis type 5 (LCA5) | Phase 1/2/3 | 2026-05-08 | Sensitivity Improvements Reaching Normal Ranges | Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases Read More | |
OPGx-LCA5 RMATOrphanRare Pediatric | Leber congenital amaurosis type 5 (LCA5) | Phase 1/2/3 | 2026-05-08 | Sensitivity Improvements Reaching Normal Ranges | Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases Read More | |
OPGx-LCA5 RMATOrphanRare Pediatric | Leber congenital amaurosis type 5 (LCA5) | Phase 1/2/3 | 2026-05-08 | Sensitivity Improvements Reaching Normal Ranges | Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IRD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IRD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IRDOpus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
Opus Genetics has provided an update on its OPGx-BEST1 Phase 1/2 clinical trial targeting BEST-1 associated inherited retinal diseases. The company expects to release three-month topline data from Cohort 1 in September 2026 and present findings at the EURETINA Congress in October. The trial aims to evaluate the safety and efficacy of OPGx-BEST1, with potential for further development based on results.
Read more →IRDOpus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
Opus Genetics has received FDA alignment on the design of its Phase 3 trial for OPGx-LCA5, a treatment for LCA5-associated inherited retinal disease. The trial will involve eight participants and aims to demonstrate significant improvement in retinal sensitivity. The company anticipates initiating dosing in Q4 2026 and may submit a BLA based on early efficacy data.
Read more →IRD▲ +7.5%on this news
Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes
Opus Genetics, a clinical-stage biopharmaceutical company, announced its inclusion in the Russell 3000®, Russell 2000®, and Russell Microcap® indexes, effective June 29, 2026. This membership reflects the company's advancements in developing gene therapies for inherited retinal diseases. The CEO expressed optimism about the increased visibility and validation this brings to their strategic initiatives.
Read more →IRDOpus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases
Opus Genetics is advancing five gene therapy programs aimed at treating inherited retinal diseases (IRDs), with four clinical data readouts expected by 2027. The company plans to initiate clinical testing for three new programs within the next 18 months, leveraging a strong cash runway that extends into 2029. The R&D Science Forum highlighted the potential for accelerated approvals and significant commercial opportunities across its pipeline.
Read more →IRDOpus Genetics R&D Science Forum
The Opus Genetics R&D Science Forum was held on June 16, 2026, highlighting the company's forward-looking statements regarding its clinical trials and product pipeline. The presentation discussed risks associated with gene therapy product candidates and emphasized the uncertainties surrounding future operating performance. A panel of experts provided insights into various topics, including clinical strategy and disease prevalence, while addressing potential challenges in patient recruitment and regulatory approvals. The forum aimed to communicate Opus Genetics' vision amidst complex industry dynamics.
Read more →IRDOpus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts
Opus Genetics will host a virtual R&D Science Forum on June 16, 2026, featuring experts discussing their gene therapy pipeline for inherited retinal diseases. The forum will cover three gene therapy programs targeting specific genetic mutations and present data from ongoing clinical programs. The event aims to highlight the company's progress and strategic plans in addressing vision loss.
Read more →IRDOpus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 28, 2026
Opus Genetics, a clinical-stage biopharmaceutical company, announced the approval of equity awards for ten new non-executive employees as part of its 2021 Inducement Plan. The awards, totaling 698,000 stock options, are designed to incentivize and attract talent in the field of gene therapies for inherited retinal diseases. The options will vest over four years, aligning employee interests with company growth.
Read more →IRDOpus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics, a clinical-stage biopharmaceutical company, has approved equity awards for ten new non-executive employees as part of its 2021 Inducement Plan. These awards, totaling 698,000 stock options, are intended to incentivize employment and are compliant with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, promoting long-term commitment.
Read more →IRDOpus Genetics to Present at the 2026 Jefferies Global Healthcare Conference
Opus Genetics, a clinical-stage biopharmaceutical company, will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026. The company focuses on gene therapies aimed at restoring vision for patients with inherited retinal diseases. Their pipeline includes several AAV-based programs targeting various genetic causes of retinal disorders.
Read more →IRDOpus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference
Opus Genetics, a clinical-stage biopharmaceutical company, will present at the RBC Capital Markets 2026 Global Healthcare Conference on May 19, 2026. The presentation will highlight the company's efforts in developing gene therapies aimed at restoring vision for patients with inherited retinal diseases. Opus Genetics has a diverse pipeline of treatments targeting various genetic causes of retinal disorders.
Read more →IRDOpus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update Opus Genetics Virtual R D Science Forum Scheduled for Tuesday
Opus Genetics reported its financial results for Q1 2026 and provided a corporate update, highlighting positive advancements in its gene therapy programs. The company anticipates important data from its OPGx-BEST1 gene therapy study in September 2026 and is working to advance multiple programs into clinical testing over the next year. They have a strong financial position, with expected cash reserves sufficient to support operations through 2029, despite a significant increase in net loss during the quarter. The FDA's acceptance of their LCA5 program into the Rare Disease Evidence Principles program marks a notable regulatory achievement.
Read more →IRD▼ -6.9%on this newsshared move
Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases
Opus Genetics presented promising clinical and preclinical data at the ARVO 2026 meeting, highlighting the potential of their gene therapies for inherited retinal diseases. Notably, their OPGx-LCA5 therapy showed significant restoration of cone-mediated vision in pediatric patients. Additionally, early results from the OPGx-BEST1 program indicated visual acuity improvements, supporting expansion into a broader patient population. The company also showcased advancements in their preclinical RHO programs, emphasizing the scalability and regulatory readiness of their therapies.
Read more →IRDOpus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study
Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study
Read more →IRDOpus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program
Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program
Read more →IRDOpus Genetics to Participate in Leading Medical Conferences in May 2026
Opus Genetics will participate in several key ophthalmology conferences in May 2026, showcasing advancements in their gene therapy programs aimed at treating inherited retinal diseases. The CEO emphasized the importance of these events for sharing progress and engaging with the community. Presentations will cover preliminary data from ongoing studies and new research developments.
Read more →IRDOpus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
Read more →IRDOpus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital
Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital
Read more →IRDOpus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
Opus Genetics has been named one of Fast Company's Most Innovative Companies of 2026 in the Biotech category. The company is recognized for its innovative gene therapies aimed at restoring vision for patients with inherited retinal diseases. CEO George Magrath emphasized the importance of patient engagement in their development process. The recognition highlights Opus's commitment to driving progress and redefining treatment outcomes in the field.
Read more →IRDOpus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update - Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts
Opus Genetics announced its financial results for the year 2025, highlighting favorable early data from its BEST1 gene therapy program presented at a key retinal experts conference. The company noted a reauthorization of the FDA's Rare Pediatric Disease Priority Review Voucher program, which supports their initiatives in rare inherited retinal diseases. While the company reported a net loss of $49.6 million, they gained $25 million from a recent funding round, extending their cash runway into 2028. Opus is advancing several therapies, including Phentolamine Ophthalmic Solution, with an upcoming FDA PDUFA date in October 2026.
Read more →IRDOpus Genetics to Present at Upcoming Investor Conferences in March 2026
Opus Genetics, a clinical-stage biopharmaceutical company, announced its participation in several upcoming investor conferences in March 2026. The conferences include the Leerink Global Healthcare Conference, Citizens Life Sciences Conference, and RBC Capital Markets Global Ophthalmology Conference. The company aims to showcase its advancements in gene therapies for inherited retinal diseases.
Read more →IRD▲ +10.9%on this news· ran to +22% by day 3shared move
Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting
Opus Genetics presented initial clinical data from its Phase 1/2 study of OPGx-BEST1 gene therapy at the Macula Society Annual Meeting. The results from the sentinel participant showed promising safety and early efficacy signals, with no adverse events reported. Improvements in visual acuity and retinal structure were noted, with full cohort data expected in mid-2026.
Read more →IRDOpus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Opus Genetics has announced that the FDA has accepted its supplemental New Drug Application for phentolamine ophthalmic solution 0.75% aimed at treating presbyopia. This age-related condition affects many adults, and if approved, the solution could provide a pharmacologic alternative to reading glasses. The FDA has set a PDUFA goal date of October 17, 2026, for the review.
Read more →IRD▲ +7.4%on this news
Opus Genetics Announces $25 Million Private Placement
Opus Genetics has announced a $25 million private placement of shares to fund its gene therapy programs aimed at treating inherited retinal diseases. The private placement involves the sale of 7,374,632 shares of Series B Non-Voting Convertible Preferred Stock. The financing is led by Adage Capital Management and is expected to close on February 18, 2026.
Read more →IRDOpus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
Opus Genetics, a clinical-stage biopharmaceutical company, announced its participation in several prominent ophthalmology and industry conferences in February 2026. These events include the Collaborative Community on Ophthalmic Innovation, the Asia-Pacific Academy of Ophthalmology Congress, and the Advanced Therapies Week Conference. The company is focused on developing gene therapies aimed at restoring vision in patients with inherited retinal diseases.
Read more →IRDOpus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa
Opus Genetics has launched a clinical trial for OPGx-MERTK, a gene therapy targeting MERTK-related retinitis pigmentosa. The trial, conducted in Abu Dhabi, aims to evaluate the safety and efficacy of the therapy, which could address a significant unmet need in treating this inherited eye disease. This initiative marks a significant advancement in precision medicine and rare disease research.
Read more →IRD▲ +6.2%on this news
Delivering on the Promise ofGene Therapy for Rare Inherited Retinal Diseases January 2026 Nargiza,BEST1 patient This presentation contains forward-looking statements within the meaning of the Private Securities Litigatio
The article discusses the advancements and challenges in gene therapy for rare inherited retinal diseases, specifically highlighting forward-looking statements regarding clinical trials and the product pipeline. It emphasizes the uncertainties and risks related to these developments, including data unpredictability and integration issues from a recent acquisition. Additionally, the success of the therapies depends heavily on the efficiency of clinical trials and regulatory approvals amid a competitive landscape. The discussion includes various factors that could impact the company's financial viability and operational capabilities in the future.
Read more →IRD▼ -5.2%on this newsshared move
Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts - Multi-asset pipeline with significant targeted data readouts and milestones - - Two lead ophthalmic gene therapy programs in clinical trials with new d
Opus Genetics highlighted its progress in 2025 and upcoming catalysts for 2026, focusing on its multi-asset pipeline for gene therapies aimed at treating inherited retinal diseases. The company anticipates significant clinical data readouts and advancements into pivotal testing for its LCA5 program. It also submitted a supplemental New Drug Application for its partnered presbyopia treatment. With over $50 million in cash resources, Opus is well-positioned to further its research and development initiatives.
Read more →IRDOpus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Read more →IRDOpus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference
Opus Genetics, a clinical-stage biopharmaceutical company, announced that its CEO, George Magrath, will present at the J.P. Morgan 2026 Healthcare Conference on January 15, 2026. The company focuses on developing gene therapies to restore vision in patients with inherited retinal diseases. Its pipeline includes several AAV-based programs targeting various retinal disorders.
Read more →IRDOpus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease
Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease
Read more →IRDOpus Genetics to Participate in Upcoming Investment Conferences
Opus Genetics, Inc. announced its participation in two upcoming investor conferences, enhancing its visibility in the biopharmaceutical sector. Chief Scientific Officer Ash Jayagopal will speak at the BTIG 5th Annual Ophthalmology Day, while CEO George Magrath will participate in the Piper Sandler 37th Annual Healthcare Conference. The company is focused on developing gene therapies for inherited retinal diseases.
Read more →IRDOpus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease
Opus Genetics has successfully dosed the first participant in its OPGx-BEST1 Phase 1/2 clinical trial aimed at treating Best disease. This gene therapy, administered via a subretinal injection, seeks to restore vision by targeting the underlying genetic mutations. Initial data from the trial is anticipated in the first quarter of 2026, marking a significant milestone for the inherited retinal disease community.
Read more →IRDOpus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update
Opus Genetics reported positive clinical data from its OPGx-LCA5 Phase 1/2 trial, which supports the potential for restoring vision. The company also had a successful FDA RMAT meeting that could expedite regulatory approval. Financially, Opus strengthened its position through a recent equity offering, although it reported a net loss of $17.5 million for the third quarter of 2025.
Read more →IRDOpus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease
Opus Genetics announced a successful FDA Type B RMAT meeting for its gene therapy OPGx-LCA5, aimed at treating LCA5-related inherited retinal disease. The FDA provided constructive feedback on the registration strategy and acknowledged the urgent medical need for treatment. The company plans to advance its ongoing trial into a Phase 3 segment, with promising early results from participants. Dosing is expected in late 2026, with topline data anticipated a year later.
Read more →IRDOpus Genetics Announces $23 Million Registered Direct Offering
Opus Genetics has announced a $23 million registered direct offering to fund its ophthalmic gene therapy clinical programs. The financing, led by Perceptive Advisors and Balyasny Asset Management, aims to support the development of its LCA5 and BEST-1 gene therapies. The offering is expected to close on November 7, 2025, and will enhance the company's cash resources into the second half of 2027.
Read more →IRDFINAL FOR GLOBENEWSWIRE Opus Genetics Announces $23 Million Registered Direct Offering - Financing led by Perceptive Advisors and Balyasny Asset Management - - Proceeds targeted to fund rapid development of ophthalmic ge
Opus Genetics has announced a registered direct offering, raising approximately $23 million to support its gene therapy clinical programs targeting inherited retinal diseases. The financing, led by Perceptive Advisors and Balyasny Asset Management, comes following a successful FDA meeting for its OPGx-LCA5 program. The funds will be allocated towards advancing the LCA5 and BEST-1 gene therapy programs, as well as for general corporate purposes. The offering is set to close on November 7, 2025, subject to customary conditions.
Read more →IRD▼ -7%on this newsshared move
Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness
Opus Genetics was featured on Good Morning America, showcasing its innovative gene therapy, OPGx-LCA5, aimed at restoring vision in patients with inherited retinal diseases. The segment highlighted Lindsey Rambo, a trial participant, emphasizing the therapy's potential to change lives. This feature coincides with the company's ongoing clinical trials and community engagement efforts.
Read more →IRDOpus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference
Opus Genetics, a clinical-stage biopharmaceutical company, will present a corporate update at Chardan's 9th Annual Genetic Medicines Conference on October 21, 2025. The presentation will be led by Dr. Ash Jayagopal, focusing on their gene therapies for inherited retinal diseases. The company is advancing its pipeline, including therapies for conditions like Leber congenital amaurosis.
Read more →IRDOpus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025
Opus Genetics will present positive clinical results from its gene therapy and Phentolamine Ophthalmic Solution programs at various conferences in October 2025. CEO George Magrath highlighted the momentum in their pipeline, including advancements in therapies for inherited retinal diseases. The presentations aim to engage the gene therapy and ophthalmology communities.
Read more →IRD▼ -7.8%on this newsshared move
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
Opus Genetics reported positive results from its Phase 1/2 trial of OPGx-LCA5, an investigational gene therapy for Leber congenital amaurosis type 5 (LCA5). The three-month data showed significant visual improvements in pediatric participants, with sustained benefits observed in adults. The company plans to discuss these results with the FDA in the upcoming quarter.
Read more →IRDOpus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions
Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions
Read more →IRDOpus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Read more →IRDOpus Genetics Appoints Rob Gagnon as Chief Financial Officer
Opus Genetics, a clinical-stage biopharmaceutical company, has appointed Rob Gagnon as Chief Financial Officer. With over two decades of experience in financial leadership, Gagnon is expected to enhance the company’s strategic finance and capital markets capabilities. His previous roles included significant achievements in capital raising and operational leadership at several biotech firms. Gagnon’s expertise comes at a critical time for Opus as it advances its pipeline and prepares for multiple regulatory milestones.
Read more →IRDOpus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September
Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September
Read more →IRDOpus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1
Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1
Read more →IRDOpus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update - Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningf
Opus Genetics announced its financial results for the second quarter of 2025, reporting noteworthy advancements in its clinical pipeline. The company revealed promising 12-month Phase 1/2 data for its gene therapy OPGx-LCA5, which targets Leber Congenital Amaurosis, alongside the Positive outcomes from Phase 3 trials for Phentolamine Ophthalmic Solution. The firm has also secured Regenerative Medicine Advanced Therapy designation from the FDA for OPGx-LCA5, supporting its potential for meaningful vision restoration. However, while continuing to advance its programs, the company also noted an increase in general and administrative expenses, alongside a reported net loss.
Read more →IRDOpus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Read more →IRDOpus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness - Collaboration aims to accelerate development of OPGx-RDH12, a gene therapy for RDH12-associated Leber
Opus Genetics has announced a partnership with the Global RDH12 Alliance to advance the development of OPGx-RDH12, a gene therapy targeting RDH12 mutations associated with Leber congenital amaurosis. This collaboration includes financial support of up to $1.6 million and aims to expedite the therapy’s path to clinical trials. The alliance combines resources and insights from advocacy groups and Opus’ gene therapy expertise, reflecting a commitment to address an urgent need for effective treatments in childhood blindness. The goal is to file an Investigational New Drug (IND) application with the FDA by late 2025.
Read more →IRDOpus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more →IRD▲ +5.1%on this news
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75 % for the Treatment of Presbyopia Study met its primary and key secondary endpoints, demonstrating rapid and
Opus Genetics has announced positive results from its VEGA-3 Phase 3 trial of Phentolamine Ophthalmic Solution 0.75% for treating presbyopia. The trial met its primary endpoint, showing a significant improvement in near visual acuity among participants treated with the solution compared to placebo. With the intention to file for FDA approval in the second half of 2025, the outcomes indicate potential advantages for adults suffering from this age-related vision condition. The trial reinforces the belief in this novel therapy's capacity to enhance vision without compromising distance acuity.
Read more →IRDOpus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program
Opus Genetics has received up to $2 million in non-dilutive funding from the RD Fund to support the preclinical development of its OPGx-MERTK program. This funding will help advance therapies for retinitis pigmentosa linked to MERTK gene mutations, an area currently lacking approved treatments. With this financial support, Opus aims to progress towards Investigational New Drug (IND) enabling studies. The RD Fund's investment reflects a strong collaboration between the biopharma industry and philanthropic efforts to accelerate breakthroughs in rare disease treatments.
Read more →IRD▲ +9.6%on this news
Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions
Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions
Read more →IRDOpus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update ARVO presentation highlights 12-month results from Phase 1/2 study that support potential of OPGx-LCA5 gene therapy to restor
Opus Genetics announced its financial results for Q1 2025, highlighting positive developments in its clinical pipeline, including the OPGx-LCA5 gene therapy which showed sustained efficacy after 12 months. The company is enrolling pediatric patients for the trial and is planning to initiate further studies. Financially, while Opus has a solid cash position of $41.8 million, it reported a net loss of $8.2 million for the quarter. The company aims to leverage recent funding to drive growth and expansion in its therapeutic offerings.
Read more →IRDOpus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May
Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May
Read more →IRDOpus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate
Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate
Read more →IRDOpus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision
Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision
Read more →IRD▼ -11.5%on this news
Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases
Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases
Read more →IRDOpus Genetics Files Definitive Proxy Statement and Sends Letter to Stockholders Highlighting the Company’s Transformation and Progress
Opus Genetics Files Definitive Proxy Statement and Sends Letter to Stockholders Highlighting the Company’s Transformation and Progress
Read more →IRDOpus Genetics to Participate in Upcoming Investor Conference in April
Opus Genetics to Participate in Upcoming Investor Conference in April
Read more →IRDOpus Genetics Announces Financial Results for Full Year 2024 Provides update on the Company's transformation and promising portfolio of innovative gene therapy treatments for inherited retinal diseases Strong cash positi
Opus Genetics has reported its financial results for the year 2024, highlighting a substantial loss of $57.5 million and an increased cash position bolstered by a recent $21.5 million financing round. The company has undergone significant transformation following its acquisition of Opus Genetics, aiming to enhance its gene therapy portfolio for inherited retinal diseases. Encouraging results from ongoing trials, especially for OPGx-LCA5, have created optimism for future milestones in 2025, which includes multiple anticipated trial data readouts. Despite earlier setbacks, Opus remains focused on advancing its strategic initiatives in the field of ophthalmology.
Read more →IRD▲ +9.6%on this news
Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million
Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million
Read more →IRD▲ +9.6%on this news
Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX
Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX
Read more →IRDOpus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
Read more →IRDOpus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs
Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs
Read more →IRDOpus Genetics Announces Updates on OPGx-LCA5 Clinical Program
Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program
Read more →IRD▲ +18.9%on this news
Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy
Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy
Read more →IRD▲ +5.2%on this news
Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024
Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024
Read more →IRDOpus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update In October, Ocuphire Pharma acquired Opus Genetics, creating a leading, clinical-stage company focused on the development of
Opus Genetics, now acquired by Ocuphire Pharma, announced its financial results for the third quarter of 2024, reporting a significant net loss of $7.5 million. The combined company has a pro forma cash balance of approximately $37 million, which is expected to sustain operations through 2026. The acquisition enhances the gene therapy pipeline, with upcoming clinical trials scheduled for 2025, including the advanced candidate LCA5 showing positive initial data in patients. Despite this promising outlook, the company faces challenges with increased expenses and a drop in revenue from the previous year.
Read more →IRDOcuphire Pharma Announces Acquisition of Opus Genetics Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations New OPGx-LCA5 Ph
Ocuphire Pharma has announced the all-stock acquisition of Opus Genetics, creating a leading company focused on gene therapy for inherited retinal diseases. The combined organization will trade under the new ticker IRD and aims to progress its pipeline of transformative therapies. Promising early data from the OPGx-LCA5 Phase 1/2 clinical trial demonstrates significant visual improvement in patients with advanced disease. The merger is expected to extend the company's cash runway into 2026, allowing for further clinical developments.
Read more →IRDOcuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology
Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology
Read more →IRDUPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia
UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia
Read more →IRDOcuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia
Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia
Read more →IRDOpus Genetics Receives Rare Pediatric Disease Designation from the U.S. FDA for Ocular Gene Therapy OPGx-LCA5 to Treat Rare Inherited Retinal Disease LCA5
Opus Genetics Receives Rare Pediatric Disease Designation from the U.S. FDA for Ocular Gene Therapy OPGx-LCA5 to Treat Rare Inherited Retinal Disease LCA5
Read more →IRDOcuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update VEGA-3 Phase 3 Study of Phentolamine Ophthalmic Solution in Presbyopia is Recruiting Patients with Top-Line Data Expected
Ocuphire Pharma announced its financial results for the second quarter of 2024 and provided updates on its clinical studies. The company is actively recruiting patients for the VEGA-3 and LYNX-2 Phase 3 trials of phentolamine ophthalmic solution, with top-line data expected in 2025. Preparations for a Phase 2/3 study of APX3330 in diabetic retinopathy are ongoing. Despite a cash position of $41.4 million, the company's net loss increased from the previous year, highlighting financial challenges.
Read more →IRDOcuphire Pharma to Present at Two Investor Conferences in August
Ocuphire Pharma to Present at Two Investor Conferences in August
Read more →IRDOcuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July
Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July
Read more →IRDOpus Genetics Announces $1.7 Million in Project-based Funding from the Foundation Fighting Blindness to Support Two Preclinical Programs
Opus Genetics Announces $1.7 Million in Project-based Funding from the Foundation Fighting Blindness to Support Two Preclinical Programs
Read more →IRDOcuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June
Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June
Read more →IRDOcuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
Ocuphire Pharma announced its financial results for Q1 2024, reporting a net loss of $7.1 million. The company highlighted advancements in its drug development, particularly with APX3330, which is being considered for treatment of diabetic retinopathy. Following a successful commercial launch of RYZUMVI by partner Viatris, Ocuphire received its first royalty payment from this product. However, the increase in general administrative expenses has raised concerns about financial management.
Read more →IRDNPDR Subset Analysis of ZETA-1 Phase 2 Trial A moderate to severe NPDR-qualifying subgroup analysis to inform future clinical trials NPDR, non-proliferative diabetic retinopathy. Primary endpoint: % of subjects with a 2
The article discusses a detailed analysis from the ZETA-1 Phase 2 trial focusing on a subgroup of patients with moderate to severe non-proliferative diabetic retinopathy (NPDR). The primary endpoint involved evaluating the percentage of subjects achieving a two-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at Week 24. Results indicated that patients treated with APX3330 had a greater treatment benefit in worsening or improvement metrics compared to those receiving placebo. The study also highlighted that APX3330 was well-tolerated overall, with mild adverse events reported.
Read more →IRDOcuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting
Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting
Read more →IRDOcuphire Pharma to Present at the Aegis Virtual Conference
Ocuphire Pharma to Present at the Aegis Virtual Conference
Read more →IRDOcuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
Read more →IRDFirst Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
Read more →IRDOcuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
Read more →IRDThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning the End-of-Phase 2
Ocuphire Pharma is advancing its pipeline with a focus on APX3330, a treatment for non-proliferative diabetic retinopathy, after successfully aligning with the FDA on study parameters at their End-of-Phase 2 meeting. The company is also preparing for the launch of RYZUMVI in early 2024, which underscores its collaborative efforts with Viatris. Despite the positives, various risks could affect Ocuphire's operations, such as regulatory challenges and market competition.
Read more →IRDOpus Genetics Announces Completion of Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy OPGx-LCA5 in Patients with Rare Inherited Retinal Disease LCA5
Opus Genetics Announces Completion of Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy OPGx-LCA5 in Patients with Rare Inherited Retinal Disease LCA5
Read more →IRDOcuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
Ocuphire Pharma reported its financial results for the fourth quarter and full year of 2023, indicating a focus on advancing its retina pipeline, particularly with APX3330 for diabetic retinopathy. The company noted a decrease in revenues and an increase in net losses compared to 2022. Despite these financial setbacks, the management expressed optimism for future growth and has sufficient cash reserves to continue operations through mid-2025. They are preparing for further clinical programs and developments in their product pipeline.
Read more →IRDOcuphire Pharma to Present in the BIO CEO & Investor Conference
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
Read more →IRDOcuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more →IRDOcuphire Pharma Strengthens Leadership Team with Key Appointments Ash Jayagopal, Ph.D., M.B.A. Appointed Chief Scientific and Development Officer Nirav Jhaveri, C.F.A, M.B.A. Appointed as Chief Financial Officer
Ocuphire Pharma has announced the appointments of Ash Jayagopal, Ph.D., M.B.A., as Chief Scientific and Development Officer, and Nirav Jhaveri, C.F.A., M.B.A., as Chief Financial Officer. The company indicates that these additions will enhance its capacity to advance its lead product candidate, APX3330, which targets diabetic retinopathy. With significant expertise in both scientific development and biopharma finance, the new appointees are expected to drive the company’s growth and innovation in treating eye disorders. The leadership team aims to address significant unmet medical needs in ophthalmology.
Read more →IRDOcuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
Read more →IRDOcuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions
Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions
Read more →IRDOcuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII
Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII
Read more →IRDOcuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer Mr. Schachle Brings Over 30 Years of Experience in Biotech and Pharma with Expertise Across Multiple Functional Areas Including
Ocuphire Pharma has appointed Joseph Schachle as its Chief Operating Officer, effective immediately. Schachle brings over 30 years of experience in the biotech and pharmaceutical sectors, having held senior roles in operations, sales, and marketing. His appointment is part of a strategic initiative aimed at advancing Ocuphire's lead retinal asset, APX3330, towards registrational studies. Schachle is particularly excited to contribute to Ocuphire’s mission of improving eye care standards and addressing diabetic retinopathy.
Read more →IRDOcuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Read more →IRDOcuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update Successful End-of-Phase 2 Meeting with FDA for Oral APX3330; Agreement on Phase 3 Registration Endpoint RYZUMVI Approved by
Ocuphire Pharma announced positive financial results for the third quarter of 2023, highlighting significant regulatory milestones. The company successfully completed an end-of-phase 2 meeting with the FDA for APX3330, gaining agreement on a primary endpoint for its phase 3 registration. Furthermore, RYZUMVI received FDA approval, supporting future commercial endeavors. The VEGA-2 phase 3 trial for presbyopia also met its primary endpoint, indicating strong progress in Ocuphire's clinical programs.
Read more →IRDNew Preliminary Clinical Data on Potential of Opus AAV-based Gene Therapy for Rare Inherited Retinal Disease to be Presented at the American Academy of Ophthalmology Annual Conference 2023
New Preliminary Clinical Data on Potential of Opus AAV-based Gene Therapy for Rare Inherited Retinal Disease to be Presented at the American Academy of Ophthalmology Annual Conference 2023
Read more →IRDOcuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy
Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy
Read more →IRDOcuphire Corporate Presentation November 2023 This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limit
Ocuphire is focused on its promising product candidates in ophthalmology, especially the recent FDA approval for Phentolamine Ophthalmic Solution. The company plans to advance its APX3330 candidate into Phase 3 trials while facing significant regulatory and funding uncertainties. Their partnership with Viatris aims to strengthen commercialization efforts, but it also presents risks that could affect market acceptance. Overall, Ocuphire's prospects illustrate both significant opportunities and potential challenges in the biopharmaceutical landscape.
Read more →IRDOcuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director Dr. Magrath Brings Proven Executive Leadership, Medical and Clinical Expertise in Ophthalmic Drug Devel
Ocuphire Pharma has appointed Dr. George Magrath as its new Chief Executive Officer and as a member of the Board of Directors. Dr. Magrath, who replaces interim CEO Rick Rodgers, is recognized for his extensive experience in pharmaceutical leadership and ophthalmology. He will lead the company's efforts in advancing clinical trials for APX3330, aimed at treating diabetic retinopathy, and continue a partnership with Viatris for the development of another ophthalmic solution. The company's strategic focus is on becoming a leading player in retinal therapy.
Read more →IRDOcuphire Pharma to Present at AAO 2023 and Eyecelerator Retina Showcase
Ocuphire Pharma to Present at AAO 2023 and Eyecelerator Retina Showcase
Read more →IRDOcuphire Pharma to Present at Euretina and Retina Society Conferences in October
Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October
Read more →IRDOcuphire Pharma and Viatris Announce FDA Approval of RYZUMVl (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrin
Ocuphire Pharma and Viatris announced that the FDA has approved RYZUMVI (phentolamine ophthalmic solution) 0.75% for treating pharmacologically-induced mydriasis due to adrenergic agonists and parasympatholytic agents. This approval allows for the commercial availability of RYZUMVI in the U.S. starting in the first half of 2024. The approval highlights a commitment to improving eye care access and has shown statistically significant efficacy in trials. The most common adverse reactions reported were site discomfort and conjunctival hyperemia.
Read more →IRDOcuphire Pharma to Participate in Three Upcoming Investment Bank Conferences
Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences
Read more →IRDOpus Genetics Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy OPGx-LCA5 in Patients with Rare Inherited Retinal Disease LCA5
Opus Genetics Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy OPGx-LCA5 in Patients with Rare Inherited Retinal Disease LCA5
Read more →IRDOcuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September
Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September
Read more →IRDAbstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposium
Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposium
Read more →IRDOcuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update End-of-Phase 2 Meeting with FDA Scheduled for Q4 2023 for Oral APX3330 in Diabetic Retinopathy (DR) Cash Balance of $40 Mi
Ocuphire Pharma announced its financial results for Q2 2023, revealing a cash balance of $40 million sufficient to fund operations through 2025. An End-of-Phase 2 meeting with the FDA is scheduled for Q4 2023 for the oral drug APX3330, which targets diabetic retinopathy and shows promise based on Phase 2 trial results. However, the company recorded a net loss of $5 million in the quarter, amid increasing administrative expenses due to various costs.
Read more →IRDOcuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in August
Ocuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in August
Read more →IRDRestore Vision & Clarity Ocuphire Corporate Presentation August 2023 2 This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements i
Ocuphire's latest corporate presentation highlights the company's advancements in treating Diabetic Retinopathy (DR) and presbyopia. APX3330 is positioned as a non-invasive oral therapy that has shown promise, with a Phase 2 trial indicating significant positive outcomes. The company has partnered with Viatris for the development of Nyxol, which targets mydriasis and is pending FDA approval. However, Ocuphire acknowledges potential risks related to regulatory hurdles and the financial resources required for ongoing product development.
Read more →IRDOcuphire to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit
Ocuphire to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit
Read more →IRDOcuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Read more →IRDOcuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association’s Annual Conference
Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association’s Annual Conference
Read more →IRDOcuphire Announces Late Breaking Presentation on APX3330 ZETA-1 Clinical Data at American Diabetes Association Annual Conference
Ocuphire Announces Late Breaking Presentation on APX3330 ZETA-1 Clinical Data at American Diabetes Association Annual Conference
Read more →IRDOcuphire Presents APX3330 ZETA-1 Data at Clinical Trials at the Summit (CTS) 2023
Ocuphire Presents APX3330 ZETA-1 Data at Clinical Trials at the Summit (CTS) 2023
Read more →IRDOcuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update End-of-Phase 2 Meeting with FDA Anticipated in 2H 2023 to Confirm Phase 3 Regulatory Path for Oral APX3330 in Diabetic Reti
Ocuphire Pharma reported its financial results for Q1 2023, showcasing a cash balance of approximately $39 million, sufficient to fund operations until 2025. The company anticipates an End-of-Phase 2 meeting with the FDA to discuss APX3330's regulatory pathway for treating diabetic retinopathy. In addition, they highlighted the upcoming PDUFA date for Nyxol's first indication in reversing pharmacologically-induced mydriasis, set for September 28, 2023. Overall, Ocuphire is making notable progress in its development programs despite a reported net loss for the quarter.
Read more →IRDOcuphire Announces APX3330 and Nyxol® Data Presentations at ASCRS 2023 and Eyecelerator
Ocuphire Announces APX3330 and Nyxol® Data Presentations at ASCRS 2023 and Eyecelerator
Read more →IRDOcuphire Provides Corporate Update and Reiterates Previous Guidance on Clinical Programs
Ocuphire Provides Corporate Update and Reiterates Previous Guidance on Clinical Programs
Read more →IRDOcuphire Appoints Rick Rodgers as Interim Chief Executive Officer Seasoned operating executive with successful track record at late-stage biopharmaceutical companies
Ocuphire Pharma has appointed Rick Rodgers as the Interim Chief Executive Officer, succeeding Mina Sooch. The company is currently in the process of searching for a permanent CEO while focusing on advancing their drug candidates, including APX3330 for diabetic retinopathy. The upcoming End-of-Phase 2 meeting with the FDA is a key focus, with the hope of solidifying the Phase 3 design for the drug. Additionally, the regulatory review process for Nyxol, which has a PDUFA date in September 2023, is being prioritized under Rodgers' leadership.
Read more →IRDOcuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update Financial Profile Improved Markedly with Global License Agreement to Develop and Commercialize Nyxol for Al
Ocuphire Pharma reported its financial results for the fourth quarter and year ended December 31, 2022, highlighting a marked improvement in its financial profile due to a global license agreement for Nyxol. CEO Mina Sooch emphasized the company's strategic advancements and preparation for crucial regulatory meetings in 2023, including a PDUFA date set for September 28 for Nyxol. Additionally, the oral drug APX3330 has achieved statistical significance in its Phase 2 trial for diabetic retinopathy, indicating promising prospects for further development.
Read more →IRDOcuphire Announces APX3330 and Nyxol® Data Presentations at ARVO 2023 Annual Meeting
Ocuphire Announces APX3330 and Nyxol® Data Presentations at ARVO 2023 Annual Meeting
Read more →IRDOcuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetings
Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetings
Read more →IRDOcuphire Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol® Eye Drops for Reversal of Mydriasis
Ocuphire Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol® Eye Drops for Reversal of Mydriasis
Read more →IRDZETA-1 APX3330 Topline Results Investor Webcast
Ocuphire Pharma held an investor webcast on January 25, 2023, to discuss the topline results from the ZETA-1 trial of APX3330. The trial demonstrated statistical significance in preventing the progression of diabetic retinopathy, supporting the potential for APX3330 as a first-line oral therapy for diabetic patients. The results were positive, but the company also acknowledged risks related to regulatory approvals and future clinical trial performances. Next steps include consulting the FDA on the potential registration pathway.
Read more →IRDOcuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA
Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA
Read more →IRDOcuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia
Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia
Read more →IRDOpus Genetics Announces Acquisition of the Rights to Two Gene Therapy Product Candidates for Inherited Retinal Diseases
Opus Genetics Announces Acquisition of the Rights to Two Gene Therapy Product Candidates for Inherited Retinal Diseases
Read more →IRDOcuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol Eye Drops for Reversal of Mydriasis NDA Supported by Positive Phase 3 Data Demonstrating Rapid Reversal of Dilated Eyes and Favorable Safety P
Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol Eye Drops for Reversal of Mydriasis NDA Supported by Positive Phase 3 Data Demonstrating Rapid Reversal of Dilated Eyes and Favorable Safety Profile in Pediatric FARMINGTON HILLS, Mich., December 6, 2
Read more →IRDOpus Genetics Receives FDA Clearance of IND Application for OPGx-001, a Gene Therapy Candidate Intended for the Treatment of Rare Inherited Retinal Disease LCA5
Opus Genetics Receives FDA Clearance of IND Application for OPGx-001, a Gene Therapy Candidate Intended for the Treatment of Rare Inherited Retinal Disease LCA5
Read more →IRDOcuphire to Present at Five Upcoming Investor/Industry Conferences
Ocuphire to Present at Five Upcoming Investor/Industry Conferences
Read more →IRDOpus Genetics Sponsors Uni-Rare Natural History Study for People with Inherited Retinal Diseases
Opus Genetics Sponsors Uni-Rare Natural History Study for People with Inherited Retinal Diseases
Read more →IRDOcuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances Ocuphire to Receive $35 Million Upfront,
Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances Ocuphire to Receive $35 Million Upfront, Nyxol Development Funding and Additional Potential Milest
Read more →IRDOcuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update NDA Submission for Nyxol for RM and Initiation of VEGA-2 on Track for Q4 2022 Topline Data from ZETA-1 Phase 2b Trial of Or
Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update NDA Submission for Nyxol for RM and Initiation of VEGA-2 on Track for Q4 2022 Topline Data from ZETA-1 Phase 2b Trial of Oral APX3330 Expected in Early 2023 FARMINGTON HILLS, Mich.
Read more →IRDOcuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol® and Strategic Partnership with American Society of Ophthalmic Administrators (ASOA)
Ocuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol® and Strategic Partnership with American Society of Ophthalmic Administrators (ASOA)
Read more →IRDOcuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting
Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting
Read more →IRDOcuphire KOL Event: APX3330
Ocuphire KOL Event: APX3330 October 14, 2022 Disclosures and Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statement
Read more →IRDOcuphire Pharma to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference
Ocuphire Pharma to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference
Read more →IRDOcuphire Pharma Hosting Key Opinion Leader Event on Oral APX3330 for Diabetic Eye Disease
Ocuphire Pharma Hosting Key Opinion Leader Event on Oral APX3330 for Diabetic Eye Disease
Read more →IRDOcuphire Expands Medical Advisory Board with Seven New KOLs and Strengthens Leadership Team
Ocuphire Expands Medical Advisory Board with Seven New KOLs and Strengthens Leadership Team
Read more →IRDOpus Genetics Expands Board of Directors with Appointment of Global Ophthalmology Leader Dr. Adrienne Graves
Opus Genetics Expands Board of Directors with Appointment of Global Ophthalmology Leader Dr. Adrienne Graves
Read more →IRDOcuphire Announces Upcoming Presentations at European Forum 2022, Eyecelerator@AAO 2022 and the American Academy of Ophthalmology 2022 Annual Meeting
Ocuphire Announces Upcoming Presentations at European Forum 2022, Eyecelerator@AAO 2022 and the American Academy of Ophthalmology 2022 Annual Meeting
Read more →IRDOcuphire Pharma Receives PDFUA Fee Waiver for Nyxol New Drug Application from FDA
Ocuphire Pharma Receives PDFUA Fee Waiver for Nyxol New Drug Application from FDA
Read more →IRDOpus Genetics Leadership to Present at 3rd Annual Gene Therapy for Ophthalmic Disorders Conference
Opus Genetics Leadership to Present at 3rd Annual Gene Therapy for Ophthalmic Disorders Conference
Read more →IRDOcuphire Pharma Announces Last Patient Completes Final Visit in ZETA-1 Phase 2b 24-Week Trial of Oral APX3330 in Diabetic Retinopathy
Ocuphire Pharma Announces Last Patient Completes Final Visit in ZETA-1 Phase 2b 24-Week Trial of Oral APX3330 in Diabetic Retinopathy
Read more →IRDOcuphire Pharma to Present at The H.C. Wainwright 24th Annual Global Investment Conference
Ocuphire Pharma to Present at The H.C. Wainwright 24th Annual Global Investment Conference
Read more →IRDOpus Genetics Hosts Inaugural Patient Advocacy Outreach Webinar on Inherited Retinal Diseases
Opus Genetics Hosts Inaugural Patient Advocacy Outreach Webinar on Inherited Retinal Diseases
Read more →IRDOcuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update Completed Final Clinical Trials and Pre - NDA FDA Meeting to Support Registration of Nyxol in Reversal of Mydriasis (R
Ocuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update Completed Final Clinical Trials and Pre-NDA FDA Meeting to Support Registration of Nyxol in Reversal of Mydriasis (RM), On Track for Late 2022 NDA Submission and Potential 2023
Read more →IRDOcuphire Pharma Announces Upcoming Presentations at Two Conferences in August
Ocuphire Pharma Announces Upcoming Presentations at Two Conferences in August
Read more →IRDOcuphire Extends U.S. Patent Protection for Late-Stage Drug Candidate Nyxol® for Reversal of Mydriasis by Five More Years into 2039 with New Patent Issuance
Ocuphire Extends U.S. Patent Protection for Late-Stage Drug Candidate Nyxol® for Reversal of Mydriasis by Five More Years into 2039 with New Patent Issuance
Read more →IRDOpus Genetics Expands its Leadership Team
Opus Genetics Expands its Leadership Team
Read more →IRDOpus Genetics to Present at OIS Retina Innovation Summit 2022
Opus Genetics to Present at OIS Retina Innovation Summit 2022
Read more →IRDOcuphire Announces Late-Breaking Paper for Nyxol for Reversal of Dilation Indication at Annual ASRS Meeting and Five More Presentations at Conferences in July
Ocuphire Announces Late-Breaking Paper for Nyxol for Reversal of Dilation Indication at Annual ASRS Meeting and Five More Presentations at Conferences in July
Read more →IRDOcuphire Granted New U.S. Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabetics and Announces New Peer-Reviewed APX3330 Publication
Ocuphire Granted New U.S. Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabetics and Announces New Peer-Reviewed APX3330 Publication
Read more →IRDOpus Genetics Appoints Ben Yerxa, Ph.D., as Permanent Chief Executive Officer
Opus Genetics Appoints Ben Yerxa, Ph.D., as Permanent Chief Executive Officer
Read more →IRDOcuphire to Present New Interim Masked Safety Data for Oral APX3330 in Diabetics at Annual Macula Society Meeting
Ocuphire to Present New Interim Masked Safety Data for Oral APX3330 in Diabetics at Annual Macula Society Meeting
Read more →IRDOcuphire Corporate Presentation
Ocuphire Corporate Presentation May 19, 2022 Disclosures and Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statement
Read more →IRDOcuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances
Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances
Read more →IRDOcuphire Pharma Announces Financial Results for First Quarter 2022 and Provides Corporate Update Nyxol Posts 5 Positive Clinical Data Readouts Including Presbyopia in Last 12 Months Successfully Enrolled 4 Late-Stage Tri
Ocuphire Pharma Announces Financial Results for First Quarter 2022 and Provides Corporate Update Nyxol Posts 5 Positive Clinical Data Readouts Including Presbyopia in Last 12 Months Successfully Enrolled 4 Late-Stage Trials for Nyxol and APX3330 in First Quarter NDA Filing on
Read more →IRDOcuphire Pharma Announces Upcoming Presentations at the Retina World Congress, Clinical Trials at the Summit, and the H.C. Wainwright Global Investment Conference
Ocuphire Pharma Announces Upcoming Presentations at the Retina World Congress, Clinical Trials at the Summit, and the H.C. Wainwright Global Investment Conference
Read more →IRDOpus Genetics Appoints Jennifer Hunt Chief Development Officer
Opus Genetics Appoints Jennifer Hunt Chief Development Officer
Read more →IRDOpus Genetics Announces Promising New Data Highlighting Potential of AAV-based Gene Therapies for the Treatment of Rare Inherited Retinal Diseases
Opus Genetics Announces Promising New Data Highlighting Potential of AAV-based Gene Therapies for the Treatment of Rare Inherited Retinal Diseases
Read more →IRDOcuphire Completes Last Clinical Trial Supporting the Planned 2022 NDA Submission with the Announcement of Positive Results from MIRA-4 Pediatric Safety Trial Evaluating Nyxol for Reversal of Mydriasis Nyxol Demonstrated
Ocuphire Completes Last Clinical Trial Supporting the Planned 2022 NDA Submission with the Announcement of Positive Results from MIRA-4 Pediatric Safety Trial Evaluating Nyxol for Reversal of Mydriasis Nyxol Demonstrated a Favorable Safety Profile and Rapidly Reversed Dilated E
Read more →IRDNew Data on Potential of Opus AAV-based Gene Therapies for Rare Inherited Retinal Diseases to be Presented at Association for Research in Vision and Ophthalmology Annual Meeting 2022
New Data on Potential of Opus AAV-based Gene Therapies for Rare Inherited Retinal Diseases to be Presented at Association for Research in Vision and Ophthalmology Annual Meeting 2022
Read more →IRDOcuphire Announces Upcoming Clinical Presentations at ARVO 2022 Medical Meeting and MODLive! 2022
Ocuphire Announces Upcoming Clinical Presentations at ARVO 2022 Medical Meeting and MODLive! 2022
Read more →IRDOpus Enters Strategic Collaboration with Resilience for AAV-based Gene Therapy Development and Manufacturing for Inherited Retinal Diseases
Opus Enters Strategic Collaboration with Resilience for AAV-based Gene Therapy Development and Manufacturing for Inherited Retinal Diseases
Read more →IRDOcuphire Pharma to Present at Wet AMD & DME Drug Development Summit in Boston, MA
Ocuphire Pharma to Present at Wet AMD & DME Drug Development Summit in Boston, MA
Read more →IRDMIRA-3 Phase 3 Trial Results Conference Call
MIRA-3 Phase 3 Trial Results Conference Call March 29, 2022 Disclosures and Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limite
Read more →IRDOcuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis
Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis
Read more →IRDOcuphire Announces Financial Results for the Fourth Quarter and Year Ended 2021 and Provides Corporate Update Building Momentum with Completion of Patient Enrollment in 4 Late-Stage Trials Multiple Late-Stage Clinical Tr
Ocuphire Announces Financial Results for the Fourth Quarter and Year Ended 2021 and Provides Corporate Update Building Momentum with Completion of Patient Enrollment in 4 Late-Stage Trials Multiple Late-Stage Clinical Trial Data Catalysts in 2022: -Nyxol MIRA-3 Phase 3 Results
Read more →IRDOcuphire Completes Enrollment of Over 100 Subjects in 24-Week ZETA-1 Phase 2b Trial of Oral APX3330 for the Treatment of Diabetic Retinopathy
Ocuphire Completes Enrollment of Over 100 Subjects in 24-Week ZETA-1 Phase 2b Trial of Oral APX3330 for the Treatment of Diabetic Retinopathy
Read more →IRDOcuphire Pharma to Present at Oppenheimer Annual Healthcare Conference
Ocuphire Pharma to Present at Oppenheimer Annual Healthcare Conference
Read more →IRDOcuphire Completes Enrollment in MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of Mydriasis
Ocuphire Completes Enrollment in MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of Mydriasis
Read more →IRDOpus Genetics Appoints Brian Leising Vice President, Manufacturing
Opus Genetics Appoints Brian Leising Vice President, Manufacturing
Read more →IRDOcuphire Completes Enrollment in MIRA-3 Pivotal Phase 3 Clinical Trial for Nyxol® in RM and Announces Two Upcoming Medical Conference Presentations
Ocuphire Completes Enrollment in MIRA-3 Pivotal Phase 3 Clinical Trial for Nyxol® in RM and Announces Two Upcoming Medical Conference Presentations
Read more →IRDOcuphire Presenting New Data and Updates on APX3330 and Nyxol Clinical Programs at Virtual Investor R&D Day New data support Phase 3 development of Nyxol alone as a durable single eye drop for the potential treatment of
Ocuphire Presenting New Data and Updates on APX3330 and Nyxol Clinical Programs at Virtual Investor R&D Day New data support Phase 3 development of Nyxol alone as a durable single eye drop for the potential treatment of Presbyopia First update on recruitment in APX3330 ZETA-1 P
Read more →IRDOcuphire Pharma Investor R&D Day
Ocuphire Pharma Investor R&D Day January 31, 2022 Disclosures And Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, stat
Read more →IRDOcuphire to Host Virtual Investor R&D Day on January 31st
Ocuphire to Host Virtual Investor R&D Day on January 31st
Read more →IRDOcuphire Provides Corporate Update: Announcing Enrollment Completion of Phase 3 Nyxol Trial, Enrollment Initiation of Nyxol Pediatric Trial, and an Investor R&D Day in January Completed Enrollment of Nyxol LYNX-1 Phase 3
Ocuphire Provides Corporate Update: Announcing Enrollment Completion of Phase 3 Nyxol Trial, Enrollment Initiation of Nyxol Pediatric Trial, and an Investor R&D Day in January Completed Enrollment of Nyxol LYNX-1 Phase 3 NVD Trial Initiated Enrollment of Nyxol MIRA-4 Pediatric
Read more →IRDOcuphire Expands Prestigious Medical Advisory Board with Six New KOLs to Support Advancement of Late-Stage Ophthalmic Assets Nyxol® and APX3330
Ocuphire Expands Prestigious Medical Advisory Board with Six New KOLs to Support Advancement of Late-Stage Ophthalmic Assets Nyxol® and APX3330
Read more →IRDOcuphire Announces Enrollment of First Patients in Second Phase 3 Pivotal Trial (MIRA-3) for Nyxol® in Reversal of Mydriasis (RM)
Ocuphire Announces Enrollment of First Patients in Second Phase 3 Pivotal Trial (MIRA-3) for Nyxol® in Reversal of Mydriasis (RM)
Read more →IRDOcuphire Announces Financial Results for the Third Quarter 2021 and Provides Corporate Update On Track to Initiate Additional Phase 3 FDA Registration Trials for Nyxol Eye Drops in Reversal of Mydriasis (RM) in 4Q21 and
Ocuphire Announces Financial Results for the Third Quarter 2021 and Provides Corporate Update On Track to Initiate Additional Phase 3 FDA Registration Trials for Nyxol Eye Drops in Reversal of Mydriasis (RM) in 4Q21 and Presbyopia in 1H22 Three Clinical Trial Data Readouts Exp
Read more →IRDOpus Genetics Announces Agreement with Massachusetts Eye and Ear and Harvard Medical School to License Third Program for Inherited Retinal Disease
Opus Genetics Announces Agreement with Massachusetts Eye and Ear and Harvard Medical School to License Third Program for Inherited Retinal Disease
Read more →IRDOpus Genetics Announces Presence at Eyecelerator@AAO 2021
Opus Genetics Announces Presence at Eyecelerator@AAO 2021
Read more →IRDOcuphire Invited to Present Clinical Data on Nyxol® and APX3330 at the American Academy of Ophthalmology 2021 Annual Meeting and Eyecelerator/AAO Meeting
Ocuphire Invited to Present Clinical Data on Nyxol® and APX3330 at the American Academy of Ophthalmology 2021 Annual Meeting and Eyecelerator/AAO Meeting
Read more →IRDOpus Genetics Announces Two Key Leadership Appointments
Opus Genetics Announces Two Key Leadership Appointments
Read more →IRDOcuphire Announces Publications Featuring the Ref-1 Protein, a Transcription Factor Regulator, as a Novel Therapeutic Target for the Treatment of Neovascular Retinal Diseases
Ocuphire Announces Publications Featuring the Ref-1 Protein, a Transcription Factor Regulator, as a Novel Therapeutic Target for the Treatment of Neovascular Retinal Diseases
Read more →IRDOcuphire’s Clinical Phase 2b Oral Drug Candidate APX3330 for Retina to be Featured at the OIS Retina@ASRS and ASRS 2021 Annual Meeting
Ocuphire’s Clinical Phase 2b Oral Drug Candidate APX3330 for Retina to be Featured at the OIS Retina@ASRS and ASRS 2021 Annual Meeting
Read more →IRDOcuphire Pharma Presenting at Three Upcoming Healthcare Conferences This Fall
Ocuphire Pharma Presenting at Three Upcoming Healthcare Conferences This Fall
Read more →IRDRD Fund Launches Opus Genetics with $19M Seed Funding to Advance Gene Therapy Treatments for Blinding Conditions
RD Fund Launches Opus Genetics with $19M Seed Funding to Advance Gene Therapy Treatments for Blinding Conditions
Read more →IRDOcuphire Pharma Presenting at Four Conferences in September
Ocuphire Pharma Presenting at Four Conferences in September
Read more →IRDOcuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update Continued Momentum in Nyxol Programs with Announcement of Positive Top-Line Results from VEGA-1 Phase 2 Trial in Presbyopia N
Ocuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update Continued Momentum in Nyxol Programs with Announcement of Positive Top-Line Results from VEGA-1 Phase 2 Trial in Presbyopia Nyxol plus Low-Dose Pilocarpine Phase 2 Trial Results Show
Read more →IRDOcuphire Pharma Presenting at Two Conferences in August
Ocuphire Pharma Presenting at Two Conferences in August
Read more →IRDOcuphire Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease
Ocuphire Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease
Read more →IRDOcuphire Selected to Present at Multiple Ophthalmic Conferences in July
Ocuphire Selected to Present at Multiple Ophthalmic Conferences in July
Read more →IRDOcuphire’s VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpoints
Ocuphire’s VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpoints
Read more →IRDVEGA-1 Phase 2 Topline Results Conference Call
VEGA-1 Phase 2 Topline Results Conference Call June 30, 2021 Disclosures and Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limit
Read more →IRDOcuphire Announces Addition to the Russell Microcap® Index
Ocuphire Announces Addition to the Russell Microcap® Index
Read more →IRDOcuphire Announces Appointment of Jay S. Pepose, M.D., Ph.D. to Its Board of Directors
Ocuphire Announces Appointment of Jay S. Pepose, M.D., Ph.D. to Its Board of Directors
Read more →IRDOcuphire Announces Closing of $15 Million Registered Direct Offering Priced At-the-Market Capital Raise Expected to Extend Runway Through Late 2022 and Allow Additional Milestones for a Potential NDA Filing for Nyxol in
Ocuphire Announces Closing of $15 Million Registered Direct Offering Priced At-the-Market Capital Raise Expected to Extend Runway Through Late 2022 and Allow Additional Milestones for a Potential NDA Filing for Nyxol in Reversal of Mydriasis FARMINGTON HILLS, Mich., June 8, 20
Read more →IRDOcuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules FARMINGTON HILLS, Mich., June 4, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and comm
Read more →IRDOcuphire to Host Key Opinion Leader Event on Nyxol® as a Potential New Treatment Option for Reversing Pharmacologically Induced Mydriasis
Ocuphire to Host Key Opinion Leader Event on Nyxol® as a Potential New Treatment Option for Reversing Pharmacologically Induced Mydriasis
Read more →IRDOcuphire Granted Two New U.S. Patents Covering Late-Stage Drug Candidate Nyxol®, Including for the Treatment of Presbyopia
Ocuphire Granted Two New U.S. Patents Covering Late-Stage Drug Candidate Nyxol®, Including for the Treatment of Presbyopia
Read more →IRDOcuphire Completes Enrollment in VEGA-1 Phase 2 Clinical Trial Investigating Nyxol® in Combination with Low-Dose Pilocarpine for Treatment of Presbyopia
Ocuphire Completes Enrollment in VEGA-1 Phase 2 Clinical Trial Investigating Nyxol® in Combination with Low-Dose Pilocarpine for Treatment of Presbyopia
Read more →IRDOcuphire Announces Financial Results for the First Quarter 2021 and Provides Corporate Update Reported Positive Data in First Pivotal Phase 3 Trial for Nyxol Eye Drops with Plans to Advance Towards NDA Submission and Com
Ocuphire Announces Financial Results for the First Quarter 2021 and Provides Corporate Update Reported Positive Data in First Pivotal Phase 3 Trial for Nyxol Eye Drops with Plans to Advance Towards NDA Submission and Commercialization in Reversal of Mydriasis Demonstrated Execu
Read more →IRDOcuphire’s APX3330 for Retinal Diseases to be Presented at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting
Ocuphire’s APX3330 for Retinal Diseases to be Presented at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting
Read more →IRDOcuphire Initiates ZETA-1 Phase 2 Clinical Trial Investigating APX3330 in Diabetic Retinopathy
Ocuphire Initiates ZETA-1 Phase 2 Clinical Trial Investigating APX3330 in Diabetic Retinopathy
Read more →IRDOcuphire Announces MIRA-2 Phase 3 Registration Trial for the Reversal of Mydriasis Meets Primary Endpoint
Ocuphire Announces MIRA-2 Phase 3 Registration Trial for the Reversal of Mydriasis Meets Primary Endpoint
Read more →IRDOcuphire Announces Financial Results for the Full Year 2020 and Provides Corporate Update
Ocuphire Announces Financial Results for the Full Year 2020 and Provides Corporate Update FARMINGTON HILLS, Mich., March 10, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercial
Read more →IRDOcuphire Announces Publication of MIRA-1 Phase 2b Results in Optometry and Visual Science Demonstrating Reduction of Pharmacologically Induced Mydriasis by Nyxol®
Ocuphire Announces Publication of MIRA-1 Phase 2b Results in Optometry and Visual Science Demonstrating Reduction of Pharmacologically Induced Mydriasis by Nyxol®
Read more →IRDOcuphire to Participate in March Investor Conferences
Ocuphire to Participate in March Investor Conferences
Read more →IRDOcuphire Initiates Enrollment in VEGA-1 Phase 2 Trial Investigating Nyxol in Presbyopia
Ocuphire Initiates Enrollment in VEGA-1 Phase 2 Trial Investigating Nyxol in Presbyopia
Read more →IRDOcuphire to Participate in the 2021 BIO CEO & Investor Conference and Cantor Fitzgerald’s Panel on Eyeing Key Events in the Ophthalmology Space in 2021
Ocuphire to Participate in the 2021 BIO CEO & Investor Conference and Cantor Fitzgerald’s Panel on Eyeing Key Events in the Ophthalmology Space in 2021
Read more →IRDOcuphire Announces Publication of ORION-1 Phase 2 Results for Nyxol in Clinical Ophthalmology and Presentation at the January OIS Presbyopia Innovation Showcase
Ocuphire Announces Publication of ORION-1 Phase 2 Results for Nyxol in Clinical Ophthalmology and Presentation at the January OIS Presbyopia Innovation Showcase
Read more →IRDOcuphire Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis
Ocuphire Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis
Read more →IRDOcuphire Corporate Presentation January 2021 Disclosures and Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.
Ocuphire Corporate Presentation January 2021 Disclosures and Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statement
Read more →IRDOcuphire Pharma Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbances
Ocuphire Pharma Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbances
Read more →IRDOcuphire to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event in Early January 2021
Ocuphire to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event in Early January 2021
Read more →IRDOcuphire to be Featured in Cantor Fitzgerald Fireside Chat with Equity Research Analyst Kristen Kluska
Ocuphire to be Featured in Cantor Fitzgerald Fireside Chat with Equity Research Analyst Kristen Kluska
Read more →IRDOcuphire Pharma Announces First Patient Enrolled in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis
Ocuphire Pharma Announces First Patient Enrolled in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis
Read more →IRDOcuphire Pharma Announces Expansion of Global Patents for Nyxol® and $1.7 Million NIH Grants for APX3330 Program
Ocuphire Pharma Announces Expansion of Global Patents for Nyxol® and $1.7 Million NIH Grants for APX3330 Program
Read more →IRDOcuphire Pharma Announces Two Publications Supporting the APX3330 Program
Ocuphire Pharma Announces Two Publications Supporting the APX3330 Program
Read more →IRDOcuphire to Participate in Upcoming Virtual HCW Conference in November
Ocuphire to Participate in Upcoming Virtual HCW Conference in November
Read more →IRDIndustry Veteran Susan Benton Joins the Ocuphire Pharma Board of Directors
Industry Veteran Susan Benton Joins the Ocuphire Pharma Board of Directors
Read more →IRDOcuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP Merger completed with Rexahn Pharmaceuticals creating a Nasdaq-listed Biopharmaceutical Company Focused on Advancing Ocuphire's Late-Stage Clini
Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP Merger completed with Rexahn Pharmaceuticals creating a Nasdaq-listed Biopharmaceutical Company Focused on Advancing Ocuphire's Late-Stage Clinical Pipeline of Ophthalmic Drug Candidates Trading under "
Read more →IRDRexahn Pharmaceuticals Announces Expected Effectiveness of Reverse Stock Split and Merger Transaction with Ocuphire Pharma
Rexahn Pharmaceuticals Announces Expected Effectiveness of Reverse Stock Split and Merger Transaction with Ocuphire Pharma
Read more →IRDOcuphire Pharma to Host Key Opinion Leader Event on Nyxol® and APX3330
Ocuphire Pharma to Host Key Opinion Leader Event on Nyxol® and APX3330
Read more →IRDRexahn Pharmaceuticals Announces Stockholder Approval of All Proposals Required for Merger with Ocuphire Pharma Rockville, Maryland
Rexahn Pharmaceuticals Announces Stockholder Approval of All Proposals Required for Merger with Ocuphire Pharma Rockville, Maryland, November 2, 2020 -- Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) ("Rexahn") announced today that at its special meeting of stockholders held on Nove
Read more →IRDOcuphire to Participate in Upcoming Virtual Healthcare Investor Conferences in September
Ocuphire to Participate in Upcoming Virtual Healthcare Investor Conferences in September
Read more →IRDRexahn and Ocuphire Enter into Definitive Merger Agreement Transaction to Create a Nasdaq-listed Biopharmaceutical Company Focused on Advancing Ocuphire's Late-Stage Clinical Pipeline of Ophthalmic Drug Candidates $21.15
Rexahn and Ocuphire Enter into Definitive Merger Agreement Transaction to Create a Nasdaq-listed Biopharmaceutical Company Focused on Advancing Ocuphire's Late-Stage Clinical Pipeline of Ophthalmic Drug $21.15 Million Investment Committed by Institutional Healthcare and Accredi
Read more →IRDOcuphire Pharma Announces In-License of Phase 2 Oral Small Molecule Drug Candidate for Diabetic Retinopathy and Diabetic Macular Edema from Apexian Pharmaceuticals
Ocuphire Pharma Announces In-License of Phase 2 Oral Small Molecule Drug Candidate for Diabetic Retinopathy and Diabetic Macular Edema from Apexian Pharmaceuticals
Read more →IRDOcuphire Pharma Announces Results from Two Phase 2 Clinical Studies of Nyxol® Eye Drops
Ocuphire Pharma Announces Results from Two Phase 2 Clinical Studies of Nyxol® Eye Drops
Read more →IRDRexahn to Explore Strategic Alternatives
Rexahn to Explore Strategic Alternatives
Read more →IRDOcuphire Pharma Announces Completion of the First of Two Phase 2b Clinical Trials for Nyxol® Eye Drops
Ocuphire Pharma Announces Completion of the First of Two Phase 2b Clinical Trials for Nyxol® Eye Drops
Read more →IRDRexahn Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Update on RX-3117 Development ROCKVILLE, MD
Rexahn Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Update on RX-3117 Development ROCKVILLE, MD - August 7, 2019 - Rexahn Pharmaceuticals, Inc. (NasdaqCM: REXN), a clinical stage biopharmaceutical company developing innovative therapies to improve
Read more →IRDOcuphire Pharma Raises Over $5 Million to Complete Multiple Late Phase 2 Clinical Trials
Ocuphire Pharma Raises Over $5 Million to Complete Multiple Late Phase 2 Clinical Trials
Read more →IRDRexahn Announces Move to Nasdaq Company will trade under the ticker symbol REXN beginning on
Rexahn Announces Move to Nasdaq Company will trade under the ticker symbol REXN beginning on June 10, 2019 ROCKVILLE, MD - May 28, 2019 - Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve pa
Read more →IRDRexahn and BioSense Global Announce Collaboration and License Agreement for RX-3117 in Greater China ROCKVILLE, MD and SUZHOU, CHINA
Rexahn and BioSense Global Announce Collaboration and License Agreement for RX-3117 in Greater China ROCKVILLE, MD and SUZHOU, CHINA - April 16, 2019 - Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage, biopharmaceutical company focused on oncology, and BioSen
Read more →IRDRexahn Effects 1-for-12 Reverse Stock Split ROCKVILLE, MD
Rexahn Effects 1-for-12 Reverse Stock Split ROCKVILLE, MD April 12, 2019 - Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today ann
Read more →IRDRexahn Pharmaceuticals Appoints Lara S. Sullivan to its Board of Directors ROCKVILLE, MD
Rexahn Pharmaceuticals Appoints Lara S. Sullivan to its Board of Directors ROCKVILLE, MD - March 1, 2019 - Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that a
Read more →IRDRexahn Presents Updated Preliminary Data on RX-3117 in Pancreatic Cancer at the 2019 ASCO GI Symposium Overall Response Rate of 38% Observed in the First 24 Patients Who Had At Least One Scan on Treatment ROCKVILLE, MD.
Rexahn Presents Updated Preliminary Data on RX-3117 in Pancreatic Cancer at the 2019 ASCO GI Symposium Overall Response Rate of 38% Observed in the First 24 Patients Who Had At Least One Scan on Treatment ROCKVILLE, MD., - Jan. 22, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceutic
Read more →IRDRexahn Pharmaceuticals Appoints Gil Price to its Board of Directors ROCKVILLE, MD
Rexahn Pharmaceuticals Appoints Gil Price to its Board of Directors ROCKVILLE, MD - December 3, 2018 - Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are d
Read more →IRDRexahn Pharmaceuticals Announces Leadership Transition Douglas Swirsky Assumes Role of Chief Executive Officer ROCKVILLE, MD
Rexahn Pharmaceuticals Announces Leadership Transition Douglas Swirsky Assumes Role of Chief Executive Officer ROCKVILLE, MD - November 14, 2018 - Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to i
Read more →IRDRexahn Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate RX-5902 (Supinoxin ) in combination with KEYTRUDA (pembrolizumab) for Triple Negative Breast Cancer ROCKVILLE, MD
Rexahn Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate RX-5902 (Supinoxin ) in combination with KEYTRUDA (pembrolizumab) for Triple Negative Breast Cancer ROCKVILLE, MD - August 21, 2018 - Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical st
Read more →IRDRexahn Pharmaceuticals Announces Collaboration with Zhejiang Haichang Biotechnology Co., Ltd. for the Development of RX-0201 (Archexin ) for the treatment of Hepatocellular Carcinoma Haichang to fund development through
Rexahn Pharmaceuticals Announces Collaboration with Zhejiang Haichang Biotechnology Co., Ltd. for the Development of RX-0201 (Archexin ) for the treatment of Hepatocellular Carcinoma Haichang to fund development through completion of Phase IIa Proof-of-Concept Clinical Trial Cl
Read more →IRDRexahn Pharmaceuticals Announces the Appointment of Douglas J. Swirsky as President and Chief Financial Officer ROCKVILLE, Md.
Rexahn Pharmaceuticals Announces the Appointment of Douglas J. Swirsky as President and Chief Financial Officer ROCKVILLE, Md., January 4, 2018 - Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics
Read more →IRDRexahn Pharmaceuticals Announces Retirement of its Founder, Chang Ahn, Ph.D., from the Board of Directors ROCKVILLE, MD.
Rexahn Pharmaceuticals Announces Retirement of its Founder, Chang Ahn, Ph.D., from the Board of Directors ROCKVILLE, MD., September 1, 2017 - Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical-stage biopharmaceutical company developing innovative, targeted therapeutics for
Read more →IRDRexahn Effects 1-for-10 Reverse Stock Split ROCKVILLE, Md.
Rexahn Effects 1-for-10 Reverse Stock Split ROCKVILLE, Md., May 5, 2017 - Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) ("Rexahn" or the "Company"), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announce
Read more →IRDRexahn Announces 1-for-10 Reverse Stock Split ROCKVILLE, Md.
Rexahn Announces 1-for-10 Reverse Stock Split ROCKVILLE, Md., April 13, 2017 - Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that it will implemen
Read more →IRDRexahn Pharmaceuticals Initiates stage 2 of Phase Ib/IIa Clinical Trial of RX-3117 in Relapsed or Refractory Metastatic Pancreatic Cancer Predefined Criteria for Preliminary Efficacy Achieved in Pancreatic Cancer Patient
Rexahn Pharmaceuticals Initiates stage 2 of Phase Ib/IIa Clinical Trial of RX-3117 in Relapsed or Refractory Metastatic Pancreatic Cancer Predefined Criteria for Preliminary Efficacy Achieved in Pancreatic Cancer Patients for Whom Three Prior Therapies had been Ineffective RX-
Read more →IRDREXAHN PHARMACEUTICALS STRENGTHENS LEADERSHIP TEAM Appoints Industry Veteran Lisa Nolan, Ph.D., Chief Business Officer ROCKVILLE, MD
REXAHN PHARMACEUTICALS STRENGTHENS LEADERSHIP TEAM Appoints Industry Veteran Lisa Nolan, Ph.D., Chief Business Officer ROCKVILLE, MD, July 11, 2016 - Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics f
Read more →IRDREXAHN PHARMACEUTICALS REPORTS INTERIM CLINICAL DATA FOR ARCHEXIN AT THE 14 TH INTERNATIONAL KIDNEY CANCER SYMPOSIUM Interim Data Show Archexin is Well Tolerated at the Doses Tested to Date with Early Evidence of Anti-Tu
REXAHN PHARMACEUTICALS REPORTS INTERIM CLINICAL DATA FOR ARCHEXIN AT THE 14TH INTERNATIONAL KIDNEY CANCER SYMPOSIUM Interim Data Show Archexin is Well Tolerated at the Doses Tested to Date with Early Evidence of Anti-Tumor Activity Observed in a Phase IIa Clinical Study in Met
Read more →IRDREXAHN PHARMACEUTICALS PRESENTS PRELIMINARY CLINICAL DATA FOR SUPINOXIN AND RX-3117 ONCOLOGY PROGRAMS AT THE EUROPEAN CANCER CONGRESS 2015 Supinoxin TM and RX-3117 Are Safe and Well Tolerated in Cancer Patients with Adva
REXAHN PHARMACEUTICALS PRESENTS PRELIMINARY CLINICAL DATA FOR SUPINOXIN AND RX-3117 ONCOLOGY PROGRAMS AT THE EUROPEAN CANCER CONGRESS 2015 SupinoxinTM and RX-3117 Are Safe and Well Tolerated in Cancer Patients with Advanced and Metastatic Solid Tumors and Demonstrate Prelimina
Read more →IRDInvestor Presentation September 2015 1 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may differ materially from antic
Investor Presentation September 2015 1 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may differ materially from anticipated results and expectations expressed in these forward-
Read more →IRD: The Trout Group LLC Tricia Truehart (646) 378-2953 ttruehart@troutgroup.com Rexahn Pharmaceuticals Announces the Appointment of Ely Benaim, M.D., as Chief Medical Officer Rockville Maryland
Rexahn Pharmaceuticals Announces the Appointment of Ely Benaim, M.D., as Chief Medical Officer Rockville Maryland, February 4, 2015 - Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment
Read more →IRD: The Trout Group LLC Tricia Truehart (646) 378-2953 ttruehart@troutgroup.com Rexahn Pharmaceuticals Appoints Richard Rodgers to its Board of Directors Rockville, MD.
CONTACTS : The Trout Group LLC Tricia Truehart (646) 378-2953 ttruehart@troutgroup.com Rexahn Pharmaceuticals Appoints Richard Rodgers to its Board of Directors Rockville, MD., Dec. 3, 2014 - Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical
Read more →IRD: The Trout Group LLC Tricia Truehart (646) 378-2953 ttruehart@troutgroup.com Rexahn Pharmaceuticals Appoints Mark Carthy to Board of Directors Rockville Maryland
ttruehart@troutgroup.com Rexahn Pharmaceuticals Appoints Mark Carthy to Board of Directors Rockville Maryland, March 3, 2014 - Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the appointment of Mark P. Carthy to the compa
Read more →IRDJanuary 2014 Revolutionizing the Treatment of Cancer 2 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may differ mater
Revolutionizing the Treatment of Cancer Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may differ materially from anticipated results, and expectations expressed in these for
Read more →IRD: The Trout Group LLC Tricia Truehart (646) 378-2953 ttruehart@troutgroup.com Rexahn Pharmaceuticals Announces Teva will not Exercise its Option to License RX-3117 Rexahn Retains its Rights to Cancer Treatment C
CONTACTS : The Trout Group LLC Tricia Truehart (646) 378-2953 ttruehart@troutgroup.com Rexahn Pharmaceuticals Announces Teva will not Exercise its Option to License RX-3117 Rexahn Retains its Rights to Cancer Treatment Compound RX-3117 Rockville, Maryland, August 28, 2013
Read more →IRD: The Trout Group LLC Tricia Truehart (646) 378-2953 ttruehart@troutgroup.com Rexahn Pharmaceuticals Announces $5.7 Million Registered Direct Offering ROCKVILLE, Md.
ttruehart@troutgroup.com Rexahn Pharmaceuticals Announces $5.7 Million Registered Direct Offering Md. July 24, 2013 Rexahn Pharmaceuticals, Inc. (the Company ) (NYSE MKT: RNN) today announced that it has received commitments from a single healthcare dedicated institutional inve
Read more →IRD: The Trout Group LLC Tricia Truehart (646) 378-2953 ttruehart@troutgroup.com Rexahn Pharmaceuticals Announce IND Submission for RX-3117 RX-3117 has potential to treat a wide variety of solid tumors including co
CONTACTS : The Trout Group LLC Tricia Truehart (646) 378-2953 ttruehart@troutgroup.com Rexahn Pharmaceuticals Announce IND Submission for RX-3117 RX-3117 has potential to treat a wide variety of solid tumors including colon, lung, renal and pancreatic tumors Rockville, Ma
Read more →IRD: Michael Mason Allen & Caron Inc. 212-691-8087 michaelm@allencaron.com Constantine Theodoropulos Base Pair Group 617-816-4637 constantine@basepairgroup.com Rexahn Pharmaceuticals Appoints Peter D. Suzdak as Chie
CONTACT : Michael Mason Allen & Caron Inc. 212-691-8087 michaelm@allencaron.com Constantine Theodoropulos Base Pair Group 617-816-4637 constantine@basepairgroup.com Rexahn Pharmaceuticals Appoints Peter D. Suzdak as Chief Executive Officer Ro
Read more →IRD: Investor Relations Constantine Theodoropulos Base Pair Group 617-816-4637 constantine@basepairgroup.com REXAHN PHARMACEUTICALS PRICES PUBLIC OFFERING OF STOCK ROCKVILLE, MD NOVEMBER 29, 2012 REXAHN PHARMACEUTI
CONTACTS : Investor Relations Constantine Theodoropulos Base Pair Group 617-816-4637 constantine@basepairgroup.com REXAHN PHARMACEUTICALS PRICES PUBLIC OFFERING OF STOCK ROCKVILLE, MD NOVEMBER 29, 2012 REXAHN PHARMACEUTICALS, INC. (NYSE MKT: RNN) today announced the pricing of
Read more →IRDInvestor Relations Stephanie Ascher Stern Investor Relations, Inc. 212-362-1200 stephanie@sternir.com Constantine Theodoropulos Base Pair Communications 617-401-3116 constantine@basepaircomm.com REXAHN PHARMACE
CONTACTS: Investor Relations Stephanie Ascher Stern Investor Relations, Inc. 212-362-1200 stephanie@sternir.com Constantine Theodoropulos Base Pair Communications 617-401-3116 constantine@basepaircomm.com REXAHN PHARMACEUTICALS PROVIDES KEY GOALS FOR 2012 Rockville, M
Read more →IRDInvestor Relations Stephanie Ascher Stern Investor Relations, Inc. 212-362-1200 stephanie@sternir.com Constantine Theodoropulos Base Pair Communications 617-401-3116 constantine@basepaircomm.com Rexahn Pharmace
CONTACTS: Investor Relations Stephanie Ascher Stern Investor Relations, Inc. 212-362-1200 stephanie@sternir.com Constantine Theodoropulos Base Pair Communications 617-401-3116 constantine@basepaircomm.com Rexahn Pharmaceuticals Announces Phase II Results for Serdaxin a
Read more →IRD: Investor Relations Stephanie Ascher Stern Investor Relations, Inc. 212-362-1200 stephanie@sternir.com Constantine Theodoropulos Base Pair Communications 617-401-3116 constantine@basepairc
CONTACTS : Investor Relations Stephanie Ascher Stern Investor Relations, Inc. 212-362-1200 stephanie@sternir.com Constantine Theodoropulos Base Pair Communications 617-401-3116 constantine@basepaircomm.com Rexahn to Raise $10 Million in Registered Direct Offering Rock
Read more →IRDInvestor Relations Stephanie Ascher Stern Investor Relations, Inc. 212-362-1200 stephanie@sternir.com Constantine Theodoropulos Base Pair Communications 617-401-3116 constantine@basepaircomm.com REXAHN ANNOUNCE
Investor Relations Stephanie Ascher Stern Investor Relations, Inc. 212-362-1200 stephanie@sternir.com Constantine Theodoropulos Base Pair Communications 617-401-3116 constantine@basepaircomm.com REXAHN ANNOUNCES CEO TRANSITION TO CSO AND SEARCH FOR NEW CEO Rockville, M
Read more →IRD: Investor Relations Stephanie Ascher Stern Investor Relations, Inc. 212-362-1200 stephanie@sternir.com Constantine Theodoropulos Base Pair Communications 617-401-3116 constantine@basepaircomm.com Teva Pharmaceu
CONTACTS : Investor Relations Stephanie Ascher Stern Investor Relations, Inc. 212-362-1200 stephanie@sternir.com Constantine Theodoropulos Base Pair Communications 617-401-3116 constantine@basepaircomm.com Teva Pharmaceutical Increases Its Investment in Rexahn for the
Read more →IRDRexahn Pharmaceuticals Announces the Appointment of Peter Brandt and Richard Kivel to Board of Directors Rockville, MD
Rexahn Pharmaceuticals Announces the Appointment of Peter Brandt and Richard Kivel to Board of Directors Rockville, MD, September 13, 2010 - Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in cl
Read more →IRD: Investor Relations Stephanie Ascher Stern Investor Relations, Inc. 212-362-1200 stephanie@sternir.com Constantine Theodoropulos Base Pair Communications 617-401-3116 constantine@basepaircomm.com Rexahn Pharmac
CONTACTS : Investor Relations Stephanie Ascher Stern Investor Relations, Inc. 212-362-1200 stephanie@sternir.com Constantine Theodoropulos Base Pair Communications 617-401-3116 constantine@basepaircomm.com Rexahn Pharmaceuticals Announces Phase IIa Study Results of Ser
Read more →IRDInvestor Relations: Industry and Press Relations: Jeffrey Goldberger / Yemi Rose Constantine Theodoropulos KCSA Strategic Communications Base Pair Communications 212-896-1249 / 212-896-123
Investor Relations: Industry and Press Relations: Jeffrey Goldberger / Yemi Rose Constantine Theodoropulos KCSA Strategic Communications Base Pair Communications 212-896-1249 / 212-896-1233 617-292-7319 jgoldberger@kcsa.com / yrose@kcsa.com Constantine@basepaircomm.com Pharmaceu
Read more →IRDJeffrey Goldberger / Yemi Rose KCSA Strategic Communications 212-896-1249 / 212-896-1233 jgoldberger@kcsa.com / yrose@kcsa.com Constantine Theodoropulos Base Pair Communications 617-401-3116 constantine@basepai
CONTACTS: Jeffrey Goldberger / Yemi Rose KCSA Strategic Communications 212-896-1249 / 212-896-1233 jgoldberger@kcsa.com / yrose@kcsa.com Constantine Theodoropulos Base Pair Communications 617-401-3116 constantine@basepaircomm.com To Raise $5 Million in Registered Direct
Read more →IRD: Investor Relations: Jeffrey Goldberger / Yemi Rose KCSA Strategic Communications 212-896-1249 / 212-896-1233 jgoldberger@kcsa.com / yose@kcsa.com Industry and Press Relations: Constantine
CONTACTS : Investor Relations: Jeffrey Goldberger / Yemi Rose KCSA Strategic Communications 212-896-1249 / 212-896-1233 jgoldberger@kcsa.com / yose@kcsa.com Industry and Press Relations: Constantine Theodoropulos Base Pair Communications 617-401-3116 constantine@basep
Read more →IRDInvestor Relations: Jeffrey Goldberger / Yemi Rose KCSA Strategic Communications 212-896-1249 / 212-896-1233 jgoldberger@kcsa.com / yrose@kcsa.com Industry and Press Relations: Constantine Theodoropulos Base Pa
CONTACTS: Investor Relations: Jeffrey Goldberger / Yemi Rose KCSA Strategic Communications 212-896-1249 / 212-896-1233 jgoldberger@kcsa.com / yrose@kcsa.com Industry and Press Relations: Constantine Theodoropulos Base Pair Communications 617-401-3116 constantine@basepa
Read more →IRD: Investor Relations: Jeffrey Goldberger / Yemi Rose KCSA Strategic Communications 212-896-1249 / 212-896-1233 jgoldberger@kcsa.com / yrose@kcsa.com Industry and Press Relations: Constantine Theodoropulos Base P
CONTACTS : Investor Relations: Jeffrey Goldberger / Yemi Rose KCSA Strategic Communications 212-896-1249 / 212-896-1233 jgoldberger@kcsa.com / yrose@kcsa.com Industry and Press Relations: Constantine Theodoropulos Base Pair Communications 617-401-3116 constantine@basep
Read more →IRD: Investor Relations: Media Relations: Jeffrey Goldberger / Yemi Rose Constantine Theodoropulos KCSA Strategic Communications Basepair Communications 212-896-1249 / 212-896-1233 617-292-731
Investor Relations: Media Relations: Jeffrey Goldberger / Yemi Rose Constantine Theodoropulos KCSA Strategic Communications Basepair Communications 212-896-1249 / 212-896-1233 617-292-7319 jgoldberger@kcsa.com / yrose@kcsa.com Constantine@basepaircomm.com Receives Acceptance of
Read more →IRDJeffrey Goldberger / Yemi Rose KCSA Strategic Communications 212-896-1249 / 212-896-1233 jgoldberger@kcsa.com/yrose@kcsa.com Rexahn Pharmaceuticals Receives Notice from NYSE Alternext US LL
CONTACT: Jeffrey Goldberger / Yemi Rose KCSA Strategic Communications 212-896-1249 / 212-896-1233 jgoldberger@kcsa.com/yrose@kcsa.com Pharmaceuticals Receives Notice from NYSE Alternext US LLC Rockville, Maryland, February 27, Pharmaceuticals, Inc. (NYSE Alternext US: RNN)
Read more →IRDBeth Bittle, Communications Manager 240-268-5300, ext. 307 REXAHN PHARMACEUTICALS APPOINTS CHIEF BUSINESS OFFICER Rockville, Maryland
CONTACT: Beth Bittle, Communications Manager 240-268-5300, ext. 307 PHARMACEUTICALS APPOINTS CHIEF BUSINESS OFFICER Rockville, Maryland, July 14, 2008 - Rexahn Pharmaceuticals, Inc. (AMEX: RNN), a leader in innovative therapeutics for life-threatening and life-debilitating
Read more →IRD: Mark (KiBong) Lee Director of Operations (240) 268-5300, extension 313 REXAHN PHARMACEUTICALS RAISES $8.6 MILLION IN PRIVATE PLACEMENT Rockville, MD
CONTACT : Mark (KiBong) Lee Director of Operations (240) 268-5300, extension 313 PHARMACEUTICALS RAISES $8.6 MILLION -- Rexahn Pharmaceuticals, Inc. (OTCBB: RXHN), a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative trea
Read more →IRDAT REXAHN: Amanda Sawney (240) 268-5300 ext. 300 REXAHN PHARMACEUTICALS, INC. APPOINTS DR. FREDDIE ANN HOFFMAN TO THE BOARD OF DIRECTORS Rockville, MD
CONTACT AT REXAHN: Amanda Sawney (240) 268-5300 ext. 300 PHARMACEUTICALS, INC. APPOINTS DR. FREDDIE ANN HOFFMAN TO THE BOARD OF Rexahn Pharmaceuticals, Inc. (OTC BB: RXHN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovat
Read more →IRDRexahn Completes Public Company Merger
Rexahn Completes Public Company Merger Rexahn now a publicly traded company (May 16, 2005) Rexahn, Corp, a biopharmaceutical company focusing on signal inhibitor therapies for cancer and central nervous system diseases, announced today the completion of a merger transaction w
Read more →Competitive Position
How IRD ranks across every disease it competes inCompetitive Position is a premium feature
See how IRD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial